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Abstract  
Objectives 
To describe the current literature on pain assessment and pain treatment for community-dwelling 
people with dementia. 
Method 
A comprehensive systematic search of the literature with narrative synthesis was conducted. Eight 
major bibliographic databases were searched in October 2018. Titles, abstracts, and full-text articles 
were sequentially screened. Standardised data extraction and quality appraisal exercises were 
conducted.  
Results  
32 studies were included in the review, 11 reporting findings on pain assessment tools or methods, 
and 27 reporting findings on treatments for pain.  
In regard to pain assessment, a large proportion of people with moderate to severe dementia were 
unable to complete a self-report pain instrument. Pain was more commonly reported by informal 
caregivers than the person with dementia themselves. Limited evidence was available for pain 
focused behavioural observation assessment.  
In regard to pain treatment, paracetamol use was more common in community-dwelling people with 
dementia compared to people without dementia. However, non-steroidal anti-inflammatory drugs 
(NSAIDs) were used less. For stronger analgesics, community-dwelling people with dementia were 
more likely to receive strong opioids (e.g. fentanyl) than people without dementia.  
Conclusion 
This review identifies a dearth of high quality studies exploring pain assessment and/or treatment for 
community-dwelling people with dementia, not least into non-pharmacological interventions. The 
consequences of this lack of evidence, given the current and projected prevalence of the disease, are 
very serious and require urgent redress. In the meantime, clinicians should adopt a patient and 
caregiver centred, multi-dimensional, longitudinal approach to pain assessment and pain treatment for 
this population.
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Key points:  
 Timely recognition of pain for people with dementia is important to ensure effective 
management and reduce adverse effects of medication.  
 Clinicians should adopt a multidimensional approach to pain assessment including self-report 
assessments, pain history information, physical examination, informant-based ratings, and 
observation of pain behaviours. 
 For patients with dementia, regular and structured medication reviews to assess the use, 
efficacy, and side effects of analgesic prescriptions are essential.  
 Further high quality, longitudinal research is essential to examine the management of pain 
and the most effective pain management strategies for community-dwelling people with 
dementia throughout the progression of disease. 
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1 Introduction  
The world’s population is ageing, with the global population of people aged 65 years and older 
projected to grow from 901 million in 2015, to almost 2.1 billion by 2050.1,2 Aligned to this population 
rise, is the increasing prevalence of dementia. In 2015, approximately 47 million people were living 
with dementia worldwide; this rate is projected to increase to 131 million by 2050.3,4 One common 
comorbidity associated with aging is painful conditions (e.g. musculoskeletal pain),5 and it is estimated 
that approximately 50% of people with dementia have a painful condition, concordant to older adults 
without dementia.6 
Symptoms associated with dementia (e.g. diminished language capacity, memory impairment, and 
behavioural symptoms) may lead to difficulties articulating a pain experience.7 Consequently, 
caregivers and clinicians may not recognise or interpret expressions of pain correctly, and thus may 
inadequately assess and treat pain.8 Poor pain management for people with dementia can cause 
adverse outcomes, such as neuropsychiatric symptoms, decreased quality of life, increased caregiver 
burden, and avoidable institutionalisation. It can also result in adverse drug events such as confusion, 
falls, and opioid overdose.9-12 Research conducted in residential, palliative, and acute care settings 
show that people with dementia are often treated differently compared to those without dementia.13-20 
Furthermore, recent randomised control trials within these settings provide evidence that a step-wise 
prescription of analgesics can lead to a reduction in a range of neuropsychiatric symptoms and mood 
syndromes.21,22 
Whilst this evidence shows the benefits of assessment and treatment of pain in people with dementia, 
the focus of such research has been largely restricted to formal care settings (e.g. nursing homes), as 
reflected in a number of existing systematic reviews23-29 and a recent meta-review.30 As a 
consequence, the evidence is almost exclusively based on people with high severity dementia (i.e. 
those without verbal communication capacity)26-28 and very little research into pain assessment and/or 
treatment has been conducted amongst community-dwelling populations.29 This highlights a 
significant knowledge gap in understanding the needs of community-dwelling people with dementia; 
this population will have greater diversity in the capacity to self-report their pain, and differences may 
exist in proxy reports from informal caregivers compared to caregivers within formal settings who may 
have professional training in assessment. Given that upward of 60% of people with dementia reside 
within community settings in the UK,31 this is a pressing concern.  
This review aims to describe the current literature on pain assessment and pain treatment for 
community-dwelling people with dementia. Specific objectives are to: i) synthesise the evidence on 
the use of pain assessment tools and methods, and assess their utility within community-dwelling 
people with dementia; and ii) synthesise the evidence on the use of pain treatments and evidence of 
efficacy for community-dwelling people with dementia.  
2 Methods 
2.1 Patient involvement 
A patient and public involvement meeting was organised with caregivers of people with dementia 
during project development. Caregivers shared their personal experiences of the complexity of pain 
assessment and management for their relative with dementia, reiterating the importance of 
systematically reviewing the evidence on pain assessment and pain treatment for community-dwelling 
people with dementia. 
2.2 Search strategy 
A comprehensive search strategy was applied within the following electronic databases: MEDLINE, 
EMBASE, AMED (Allied & Complementary Medicine Database), AgeLine, CINAHL, PsycINFO, Web 
of Science Core Collection, and The Cochrane Library from inception to October 2018 (see 
supplementary Table S1 for the MEDLINE search strategy). Searches were designed and conducted 
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by LB with agreement and oversight from PC, JB, and JJ (research information specialist). No search 
limits were applied for study design, date, or language of publication. Further supplementary searches 
were conducted in Google Scholar, and all reference lists of all included papers were hand screened. 
A citation search of all included papers were tracked to ascertain subsequent potential publications, 
as well as a screen of all reference lists of relevant commentaries, literature reviews, and systematic 
reviews. 
2.3 Criteria for considering studies for this review 
Inclusion 
 Study participants must have a confirmed diagnosis of dementia and reside in the community 
(including living alone at home, with informal caregivers at home, retirement communities, 
warden-controlled housing, or assisted living).31  
 Studies examining the use of self-report, informant-report, and behavioural observation tools 
and methods of pain assessment.32 
 Studies examining the use of treatments for pain (including pharmacological, and non-
pharmacological treatments for pain). 
 Studies evaluating the effectiveness of treatments for pain (both pharmacological and non-
pharmacological) with a pain assessment tool.  
 Full text peer-reviewed scientific journal articles.  
 Studies published in English or other languages translatable via colleagues at the Research 
Institute. 
Exclusion 
 Studies with participants with dementia in nursing home, palliative, or hospital settings. If a 
study includes participants with dementia living in a variety of residential settings (e.g. nursing 
home and community), the study will be excluded if the results specific to people with 
dementia living in the community cannot be extracted independently. 
 Studies solely focused on malignant pain. Cancer pain and its management is distinctly 
different from other common pain conditions. 
Inclusion of papers involved a number of stages:  
 Title screen to remove obviously irrelevant references (LB).  
 Abstract screening and full text screening (LB), with 20% of the abstracts and full texts 
screened independently by PC with good interrater agreement (>95%). Discrepancies were 
resolved in discussion with a third reviewer (JB).  
2.4 Data extraction 
Data extraction was completed by LB and checked for consistency and accuracy by two other authors 
(PC and JB). Data were extracted onto a standardised data extraction form. The extracted data 
included: participant characteristics and information on the type of pain assessment and pain 
treatments. LB contacted the authors of potentially eligible papers if additional information or 
clarification was required.  
2.5 Quality appraisal 
Study quality was assessed using the National Institute of Health (NIH) Quality Assessment toolkit33 
for a number of study designs (case-control, observational cohort, cross-sectional, controlled 
intervention, and pre-post studies with no control group). Each tool consists of 11 to 14 items 
(dependent on design type), each evaluated as “yes”, “no”, or “not applicable/cannot decide” as 
guided by NIH guidance. Each item focused on the concepts, questions, and domains that are 
integral for the critical appraisal and evaluation of internal validity, including potential biases, 
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confounding, and study power. Each item was used to guide the overall quality rating of "good," "fair," 
or "poor". A 20% sample of the studies were blind checked by PC to ensure consistency. 
Discrepancies were resolved in discussion with a third reviewer (JB).  
2.6 Analysis 
Due to heterogeneity of the sample populations, settings, study designs, interventions, and reported 
outcomes, as well as a lack of statistical information to perform a meta-analysis, a narrative approach 
was adopted. The initial analysis stage assessed and described the quality of the included studies. 
Each study was assigned to the overarching theme or “cluster”34 of “pain assessment” and/or “pain 
treatment”. Studies were further clustered thematically to form sub-domains. Sub-domains for pain 
assessment were self-report, informant-report, and behavioural observation. Sub-domains for pain 
treatment were pharmacological (further clustered by analgesic potency) and non-pharmacological 
treatments. Studies were tabulated based on their domain and sub-domain to allow for preliminary 
comparison within and across studies. The systematic approach to the narrative synthesis allowed the 
identification of patterns across the data in order to draw informative conclusions relevant to current 
research, policy, and practice.34  
3. Results 
Searches identified 6741 unique records (up to October 2018), of which 129 were screened at full-text 
stage. One potentially eligible paper could not be obtained in full text.35 Three additional papers were 
found through the supplementary searching, resulting in 32 studies included within the review (See 
Figure 1). Of the included studies, 11 reported findings on pain assessment tools or methods (see 
Table 1), whereas 27 reported findings that explored treatments for pain (see Table 2 for an overview 
of pain treatment use and Table 3 for pain treatment effectiveness). 16 studies were conducted in 
North America, 8 in Finland, 2 in Denmark and 1 each in Canada, Northern Ireland, Sweden, France, 
Japan and Italy.  
[Insert Figure 1] 
3.1 Quality assessment 
Using the NIH Quality Assessment tools, 4 studies (12%) were assessed as good quality, 21 (66%) as 
fair quality, and 7 (22%) as poor quality. 
Observational study designs were assessed using the NIH Quality Assessment Tool for Observational 
Cohort and Cross-Sectional Studies. Many questions in the tool received a high percentage of “no” 
responses largely because of the cross-sectional designs. For example, only seven (22%) studies 
investigated the exposure prior to the outcome (question 6), four (13%) provided sufficient timeframe 
for the outcome to occur (question 7), and three (9%) measured the exposure more than once during 
the study period (question 10). A “no” response did not necessarily lead to a poor quality rating, but 
rather indicated areas of potential biases that may influence the relationship between the exposure 
and outcome associated with cross-sectional designs. Intervention studies were quality assessed 
using the NIH Quality Assessment Tools for Controlled Intervention Studies, or Pre-post Studies with 
No Control Group depending upon the presence of a comparator group (see supplementary Table S2 
for detailed quality assessment). 
3.2 Pain assessment tools and methods 
Eleven studies investigated pain assessment tools and methods for community-dwelling people with 
dementia. Five studies examined self-report pain tools, six studies examined informant-based ratings 
of pain, and one study examined a behavioural observation tool. 
Only one study provided an overview of the frequency of pain assessment in primary care,37 with pain 
assessment documented in 98% of patients’ medical records. Of the pain assessments documented 
in this study, 98% used the Numerical Rating Scale (NRS), Visual Descriptor Scale (VDS), or Faces 
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Pain Scale (FPS), whereas only 2% of medical records reported modifications of pain scales for 
cognitive impairment. 
3.2.1 Self-report 
Four studies (1 good quality,36 1 fair quality,37 and 2 poor quality38,39) examined the utility of the FPS, 
Visual Analogue Scale (VAS), Pain Intensity Scale (PIS),39,40 and the Philadelphia Geriatric PIS.36,37 
The completion rates of the FPS, VAS and PIS were between 53-67% for people with largely 
moderate to severe dementia (Mini Mental State Examination (MMSE) of 15.6, ± 5.9 SD; MMSE of 
15.7, ± 5.9 SD).38,39 Two studies considered the Philadelphia Geriatric PIS and results show it was 
predictive of negative psychosocial events at 4 months follow up,36 and identified a greater 
percentage of pain than reported in the medical records using the NRS, VDS, or FPS (94% vs 36%, 
respectively).37  
3.2.2 Informant pain ratings  
In total, seven studies (4 fair,40,41,42,43 and 3 poor quality39,44,45) investigated informant-pain ratings of 
pain for community-dwelling people with dementia using a variety of tools (VDS,40,43,44 EQ5D,41,42 the 
Philadelphia Geriatric PIS,45 FPS, VAS, PIS39). Five of these studies compared the percentage of self-
reported and informant-reported pain for community-dwelling people with dementia.40-44 Caregivers 
reported pain presence in the person with dementia more frequently than the person with dementia 
themselves (see Figure 2). In the three studies investigating the congruence between people with 
dementia and their caregiver’s rating of pain an inter-rater reliability ranged from 0.25 to 0.34,39,41,42 
with an average agreement of 58.6% in the two fair quality studies (range 58.2% to 59%).42,43  
[Insert Figure 2] 
3.2.3 Observation of pain behaviours   
One poor quality study investigated the Hospice Approach Discomfort Scale, a rating tool for 
observation of behaviours.39 Such tools aim to identify pain using non-verbal cues (e.g. behaviour, 
facial expression, body language).46 Poor correlations between the Hospice Approach Discomfort 
Scale and self-reported pain scales (FPS, VAS, and PIS) were reported; however, the author did not 
provide statistical evidence to support the findings and therefore estimations of concordance cannot 
be reported. 
3.3 Treatments for pain  
27 papers provided an overview of treatments for pain for community-dwelling people with dementia. 
22 papers (3 good,47,48,49 16 fair,19,37,40,41,50-53,55-61 3 poor quality38,44,62) provided an overview of the 
pain treatments used by people with dementia.  
3.3.1 An overview of analgesic use  
Two papers investigated the use of analgesics for community-dwelling people with dementia over 
time, irrespective of their analgesic potency.47,55 Hamina et al55 examined analgesic use during the 
first 180 days after dementia diagnosis, stratified by the year of diagnosis (from 2005 to 2011). People 
diagnosed with dementia in 2011 were 2.3 times more likely to be prescribed analgesic medication 
during the first 180 days after diagnosis than people diagnosed with dementia in 2005. Alternatively, 
Gilmartin et al47 examined analgesic use from the time of dementia diagnosis, to five years after 
dementia diagnosis. Analgesic use remained largely consistent. These fair and good quality studies 
point more strongly towards changes with prescribing practices over time (cohort effect), irrespective 
of age and dementia severity. 
11 papers reported an average 41.4% (range 24.7% to 63%) of people with dementia used analgesic 
medication.19,37,38,40,50,51,54,55,58,60,62 Four papers found that 47.7% (range 30.3% to 68%) of people with 
dementia reporting pain did not use analgesic medication.41,44,57,59 When exploring the prevalence of 
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analgesic use by community-dwelling people with dementia compared to a reference group, four 
papers (fair quality) found a mixed trend, with community-dwelling people with dementia having a 
lower51,52 or similar19,55 prevalence of analgesic medication compared to community-dwelling older 
adults without dementia. 
3.3.2 Categories of Analgesics prescribed  
3.3.2.1 Paracetamol 
Paracetamol was used by an average 23.9% (range 12% to 32%) of people with dementia.19,38,40,55 
The amount of paracetamol used by community-dwelling people with dementia (with the exception of 
Hamina et al55) included over-the-counter and prescribed paracetamol. Evidence suggests 
community-dwelling people with dementia use paracetamol more commonly than community-dwelling 
people without dementia.19,55 
Longitudinal research suggests that the use of paracetamol increased from the first year after 
dementia diagnosis to five years post-diagnosis.47  
3.3.2.2 Nonsteroidal anti-inflammatory drugs (NSAIDs) 
Across all studies the combined prevalence of over-the-counter and prescribed NSAID use was 12% 
(range 5.9% to 21%).19,38,40,55 Lower rates of NSAID use19  and prescriptions55 was found for 
community-dwelling people with dementia compared to community-dwelling people without dementia 
(5.9% vs 12%, respectively),19 and matched controls (13.2% vs 17.3%, respectively).55 
NSAID use decreased from the first year after dementia diagnosis to five years post-diagnosis.47 
Additionally, the amount of NSAIDs prescribed during the first 180 days after dementia diagnosis also 
decreased each year from 2005 to 2011 for community-dwelling people with dementia,55 suggesting a 
change in the practice of prescribing NSAID medication over time, irrespective of age and dementia 
progression. 
3.3.2.3 Opioids 
The prevalence of opioid use for community-dwelling people with dementia was on average 14.3% 
(range 7.1% to 27.5%).19,38,40,48-50,53,55,56 Three studies (two fair quality,55,56 and one good quality48) 
show that community-dwelling people with dementia were prescribed less opioids than age, sex, and 
region of residence matched controls without dementia. However, two studies19,53 (both of fair quality) 
showed that more community-dwelling people with dementia used19 or were prescribed53 opioid 
medication compared to community-dwelling people without dementia (see Figure 3).  
The use of opioids for community-dwelling people with dementia was relatively consistent from the 
first year after dementia diagnosis to five years post-diagnosis.47 However, the amount of opioids 
prescribed during the first 180 days of dementia diagnosis increased each year from 2005 to 2011,55 
with those diagnosed in 2011 being 3.7 times more likely to be prescribed an opioid during the first 
180 days after dementia diagnosis compared to those diagnosed in 2005. 
[Insert figure 3] 
When opioid use was stratified further based on strength defined by the World Health Organisation’s 
(WHO) Analgesic Ladder, an average 9.8% (range 2.7% to 16.8%) of people with dementia were 
prescribed weak opioids, whereas the proportion prescribed strong opioids was 5.3% (range 0.95 to 
17.4%).37,53,55,56 The annual prevalence of strong opioid use was higher among community-dwelling 
people with dementia compared to the reference group.53,56 Community-dwelling people with 
dementia had a 1.44 higher odds of being prescribed fentanyl than matched controls,56 and a two 
times higher odds than a comparison group without dementia.53 Additionally, community-dwelling 
people with dementia had a two times higher odds of being prescribed buprenorphine than 
community-dwelling people without dementia.53 
  
 
This article is protected by copyright. All rights reserved. 
3.4. The effectiveness of treatments for pain 
Five papers investigated the effectiveness of treatments for pain for community-dwelling people with 
dementia by measuring the result of an intervention upon pain assessment scores (1 fair quality,63 4 
poor quality45,62,64,65). Two papers investigated analgesic treatments63,64 with three investigating a non-
pharmacological treatment/intervention for pain.45,62,65 
Elliot and Horgas64 investigated the effectiveness of scheduled paracetamol in reducing pain 
behaviours (e.g. rubbing, grimacing, and sighing) among those with musculoskeletal pain. Observed 
pain behaviours were lower in treatment phases than during baseline phases. Benedetti et al63 found 
no difference in pain scores between an expected or unexpected application of 1% lidocaine during 
the insertion of a needle. However, the difference between the open applications decreased between 
baseline and follow up. 
One study investigated the effectiveness of a non-pharmacological music intervention upon pain for 
this population.65 Informal-caregivers assessed pain 30 minutes before, during, and after listening to 
music. Many comparisons indicated non-significant findings; however, pain was significantly lower 
after listening to music than before listening to music. Two studies45,62 investigated the effectiveness 
of psychosocial interventions with mixed efficacy (see Table 3).  
4 Discussion 
This review provides an overview of the current evidence on both pain assessment and pain 
treatment for community-dwelling people with dementia. These two areas will be discussed in turn, 
contextualised by contrasting with comparative population groups, and considering implications for 
practice, research and policy.  
Pain assessment 
The first aim of this review was to synthesise evidence on the use of pain assessment tools and 
methods, and their utility for community-dwelling people with dementia. A large proportion of those 
who have moderate to severe dementia were unable to complete a self-report pain instrument,38,39 
suggesting a threshold effect for their efficacy in this population. Such findings are in line with the 
British Pain Society (BPS) recommendations that encourage the use of self-report measures for 
people with dementia (irrespective of their degree of cognitive ability); however certain adaptations 
(e.g. simplified language and large fonts) may be required, especially for those with moderate and 
severe cognitive impairment.7,66 Overall, whilst self-report pain assessments can be used in 
community-dwelling people with dementia, a reliance on self-report methods in isolation is not 
recommended, especially for people with moderate-to-severe dementia.7 
Informant-ratings by informal caregivers show a discrepancy compared to the person with dementia’s 
self-report rating of pain, with caregivers reporting the person with dementia to be in pain more 
commonly than the person themselves. Interestingly in nursing home settings, similarities across 
informant-ratings are evident,68 however nurses and nursing assistants rate people with dementia to 
experience less pain than self-ratings.69 Such findings contradict findings from this review, indicating 
potential differences dependant on the environment of care. Certainly informant “over and under” 
estimations of pain are likely to have negative implications for treatment of pain for people with 
dementia.14,18 Studies investigating informant-ratings of pain included in this review used self-report 
instruments (such as the VDS and EQ5D) to compare informant and self-reports of pain. Tools 
created specifically for caregiver informant-use (e.g. Pain Assessment for the Dementing Elderly; 
PADE,69 Pain Assessment in Noncommunicative Elderly Persons; PAINE,70 Abbey Pain Scale71) are 
yet to be tested, or validated within community-dwelling people with dementia.  
This review identified only one, low quality study examining a behavioural observation pain 
assessment tool and the conclusions from this study suggest a poor correlation with self-report 
methods. Previous reviews have evaluated behavioural observation pain tools for people with 
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dementia residing in formal care settings.26,45,72,73 These reviews suggest that behavioural observation 
pain tools hold promise to identify pain for people with dementia (e.g. PAINAD, PACSLAC, 
DOLOPLUS2 and ECPA).45,74 However further psychometric development and testing is essential.26,46 
Behavioural observation tools may be suitable for community-dwelling people with dementia however, 
the lack of testing and development in this setting, as illuminated by this review, hinders the ability to 
provide definitive conclusions. 
Treatment of pain 
In the second aim of this review, the synthesis of evidence on the use of pain treatments for 
community-dwelling people with dementia indicates that community-dwelling people with dementia 
had less or similar analgesic prescriptions than comparator groups. This mixed evidence may be 
explained by the varying healthcare organisation and funding models across each region (USA, 
Finland, and Sweden). In nursing home settings, the large majority of evidence to date has found 
people with dementia are prescribed less pain medication than their matched controls.14,75,76 
When analgesic medications were stratified into therapeutic classifications, community-dwelling 
people with dementia more commonly used paracetamol compared to community-dwelling older 
adults without dementia, with similar findings also evident in nursing home settings.6,19,20 The notable 
preference towards paracetamol is consistent with recommendations suggesting paracetamol as a 
first-line analgesic treatment.23,77 The recent focus of pain in people with dementia may have 
contributed to increased paracetamol use, as an attempt to provide adequate treatment for this 
vulnerable population.  
This review found that NSAID prescribing is lower for people with dementia compared to those without 
a dementia diagnosis, and that NSAID use decreased over time for people with dementia. The 
findings from this review reflect National Institute for Health and Care Excellence (NICE) guidelines 
(2015)78 that advises that NSAIDs should be prescribed with caution for older adults due to the 
associated risks of gastrointestinal bleeding/perforation, renal dysfunction, and cardiovascular 
events,79,80 and only if alternative safer treatments have not provided sufficient pain relief.81-83 Similar 
trends in NSAID use are also evident for people with dementia living nursing home settings.84 
Cognitive impairment and certain vascular-based types of dementia may be perceived as an 
additional risk factor for NSAID treatment and may contribute to caution in prescription. The reduction 
of NSAID prescriptions may have contributed to the increased use of paracetamol as a compensatory 
treatment.19 
This review identified three studies48,55,56 that found less community-dwelling people with dementia 
were prescribed opioids, however, two studies19,53 found that more community-dwelling people with 
dementia used opioid medication compared to comparator groups without dementia. Differences 
between the studies may contribute to the unclear findings; opioid prescriptions were identified at the 
time of the research interview,19 during a six-month period of dementia diagnosis,55 or a one-year 
period (during 2005).56 A much larger percentage of opioid prescriptions were evident when the length 
of investigation increased to a 5-year period potentially because of cohort effects.48 A recent 
systematic review investigating opioid use for people with dementia (irrespective of residential status) 
found that they used less opioids than people without cognitive impairment.85 High quality research to 
further explore opioid use for community-dwelling people with dementia is essential to determine if the 
findings align to those found in other residential settings, and to further understand the implications for 
effective management. 
When opioid prescriptions were stratified into weak and strong opioids, this review found that fentanyl 
and buprenorphine were prescribed more commonly to people with dementia compared to matched 
controls.48,53,55 In nursing home settings, research suggests that older adults with cognitive impairment 
were more likely to receive fentanyl transdermal patch formulations as a first line treatment for 
pain.86,87 Fentanyl and buprenorphine may be favoured for people with dementia due to the benefits of 
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transdermal patch formulations for those with swallowing difficulties, impaired gastrointestinal 
function, and/or a reduced analgesic compliance.85,88  
Finally, this review aimed to evaluate the effectiveness of pharmacological and non-pharmacological 
treatments; however, evidence was limited and low quality. Scheduled paracetamol treatment 
reduced pain scores for people with dementia. Such findings are comparable to larger trials 
conducting in nursing home settings.21,22 Additionally, experimental evidence suggests people with 
dementia may require more analgesia to reach the appropriate level of pain relief, questioning the 
current efficacy of analgesic treatment for people with dementia based on routine prescribing 
regimes,63 however more research is essential prior to confirm this finding. This review identified only 
poor quality papers investigated the efficacy of non-pharmacological treatments (including music, and 
psychosocial interventions) for pain in community-dwelling people with dementia. Other systematic 
reviews report that non-pharmacological treatments (e.g. music therapy, Reiki, reflexology, person-
centred showering or bathing) can be effective in reducing pain for people with dementia living in 
formal care.89  
4.3 Strengths and limitations 
This review has notable strengths. It is the first to provide a broad overview of the evidence on pain 
assessment and treatment for pain for community-dwelling people with dementia. The search strategy 
developed in collaboration with experienced information specialists is comprehensive with extensive 
supplementary searches. This review reports on the quality of evidence from the included studies, 
which has highlighted a low level of quality evidence on this topic within community-dwelling 
populations of those with dementia. 
There are, however, limitations that are important to consider. Some studies90-95 provided information 
on pain assessment or pain treatment for people with cognitive impairment, using standardised 
instruments such as the MMSE, however these studies did not provide sufficient information to 
confirm that participants had a diagnosis of dementia and were therefore not included in the review. 
Finally, the conclusions of this review need to be contextualised within the limited research to date; 12 
studies actively recruited participants with mild-to-moderate, or newly diagnosed dementias, with 
many more recruiting an insufficient number of participants with severe dementia. Therefore, the 
extent of evidence on more severely affected community-dwelling people with dementia is limited and 
more evidence is required in this sub-population. 
4.4 Clinical implications 
Due to the minimal high quality research to date, this review was unable to provide definitive 
conclusions regarding a pain assessment tool or method to recommend for use with community-
dwelling people with dementia. Clinicians should therefore adopt a multidimensional approach using 
“a hierarchy of pain assessment techniques” including self-report assessments, pain history 
information, physical examinations, informant-based ratings, and observation of pain behaviours, in 
line with previous recommendations.96 Reliance on one method alone may lead to suboptimal 
assessment and treatment. 
In terms of analgesic use, adverse effects, comorbidities, and polypharmacy are common in older 
adults, with the added complexity of cognitive impairments associated with dementia and the already 
outlined challenges in pain assessment. Due to these complexities, regular and structured medication 
reviews are needed to assess the use, efficacy, and side effects of analgesic prescriptions, especially 
so as changes to cognitive ability are evident over the course of the disease. Care is particularly 
needed when new medications, particularly transdermal analgesics that are initiated to manage 
pain,97 to balance the risk of adverse drug reactions against the ease of transdermal patch 
administration of opioids.56 In conjunction with pharmacological strategies, prescribing clinicians 
should consider the use of non-pharmacological strategies to minimise drug related adverse events. 
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4.5 Research Implications 
In regard to pain assessment, research comparing multiple pain assessment instruments for a range 
of dementia severities using a clear, and pre-defined protocol within a community sample is required. 
High quality evidence is essential to assess the psychometric properties and clinical utility of pain 
assessment instruments (including self- and informant-based measures, and behavioural observation 
pain tools) for community-dwelling people with dementia.  
Future research investigating treatments for pain should stratify analgesia by therapeutic 
classification, with a focus towards high quality longitudinal evidence to encompass the person with 
dementia’s progression. Such evidence is essential to provide a basis for future randomised control 
trials, alike to those conducted in nursing home settings.21,22,98  
5 Conclusions 
This review identifies a dearth of high quality studies exploring pain assessment and/or treatment for 
community-dwelling people with dementia, not least into non-pharmacological interventions. The 
consequences of this lack of evidence, given the current and projected prevalence of the disease, are 
very serious and require urgent redress. In the meantime, clinicians should adopt a patient and 
caregiver centred, multi-dimensional, longitudinal approach to pain assessment and treatment in this 
population. 
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Table 1 Summary of pain assessment studies 
Author Orgeta et al42 Shega et al43,100 Jensen-Dahm et al41 Breland et al58 Snow et al36 
Sub-theme Informant rating Informant rating Informant rating Self-report Self-report 
Design Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cohort 
Origin USA USA Denmark USA USA 
Diagnosis Dementia Dementia AD or DLB Dementia Dementia 
n (reference/control) 488 115¶ 321¶ 136 171¶ 
Quality Fair Fair Fair Fair Good 
Pain assessment tool EQ5D VDS EQ5D PGC PIS PGC PIS 
Completion rate % - - - - - 
PWD (caregivers) % [p] 45 (59) [p<.001] 32 (53) 32.9 (52) - - 
Informant agreement 58.2% 
Kappa = 0.25 
59% congruent  
40% over report 
13% under report 
Kappa = 0.34 
(X2 = 71.7, df= 4; 
p<.001) 
- - 
Convergence with 
alternative pain 
assessment 
- - - - - 
Predictive validity - - - Pain diagnosis in 
previous year (β=.20, 
t132=2.17, p<.05) 
Increased depression 
(z=2.70) agitation (z= 2.33) 
decreased pleasant events 
(z=-2.38) 
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Table 1 cont. Summary of pain assessment studies 
Author Barry et al40 Li et al37 Brummel-Smith et 
al38 
Krulewitch et al39 Hunt et al44 Kunik et al45 
Sub-theme Informant rating Self-report Self-report Self-report 
Informant rating 
Behavioural observation 
Informant rating Informant rating 
Design Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional Intervention 
baseline 
Origin Ireland USA USA USA USA USA 
Diagnosis Dementia Dementia Dementia  Dementia Dementia Dementia 
n 
(reference/control) 
75† 203 154 (255) 156¶ 802 (802) 203 
Quality Fair Fair Poor Poor Poor Poor 
Pain assessment 
tool 
VDS PGC PIS FPS, VAS, PIS FPS, VAS, PIS, HADS VDS PGC PIS 
Completion rate 
% 
- - 32.5 PIS, 62; FPS, 53; VAS, 
53 
33 unable to complete 
FPS, VAS, or PIS  
- - 
PWD (caregivers) 
prevalence % [p] 
Pain now - 36 (53.3) 
[p=.033] 
Average day – 57.3 
(70.7) [p=.089] 
- - - Activity limit 40.1 
(46.6) 
[p= .03] 
Bothersome 62.7 
(64.4) [p=.59] 
- 
PWD (caregiver) 
mean pain score  
- - - - - Worst pain: 2.93 
(3.15) Overall pain: 
2.04 (2.24) 
Informant 
agreement 
- - - kappa = .32 
PIS (rho=.452; p<.001) 
VAS (rho=.420; p<.001) 
FPS (rho=.417; p<.001) 
HADS: NR 
- - 
Convergence with 
alternative pain 
assessment 
- 94% PGC PIS 
36.4% medical 
record 
- - -  
Predictive validity - - - - -  
¶ dyadic paired participants (e.g. person with dementia and their caregiver). 
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Abbreviations: CI, confidence interval; FPS, faces pain scale; HADS, Hospice Approach Discomfort Scale; IPT, Iowa Pain Thermometer; NR, not reported; 
NRS, numerical rating scale; OR, odds ratio; PGC, Philadelphia geriatric centre; PIS, pain intensity scale; PWD, people with dementia; VAS, Visual 
Analogue Scale; VDS, visual descriptor scale. 
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Table 2 Summary of pharmacological pain treatment studies 
Author Hartikainen et 
al50,99 
Mäntyselkä et al51 Schmader et al52 Jensen-Dahm et al41  Jensen-Dahm et 
al53 
Haasum et al19 
Design Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional 
Origin Finland Finland USA Denmark Denmark Sweden 
Diagnosis Dementia Dementia Dementia Dementia Dementia Dementia 
n (reference) 75 (446) 75 (446) 100 (420) 321¶ 35,455 (870,645) 119 (2199†, 186‡) 
Quality Fair Fair Fair Fair Fair Fair 
Analgesic use % 
(control %) 
63  
 
33.3 (47.3) - 51.5†† 
8.3 received >1 
- 36 (24.3†, 52.7‡) 
Analgesic use, 
PWD vs control 
[OR (95% CI)] 
- - 0.54 (0.39 to 
0.75) 
- - Nursing home vs 
community 1.72 
(0.96 to 3.10)§ 
Paracetamol use 
% (control %) 
58 (paracetamol 
and NSAID) 
- - - - 24.4 (15.4†, 45.2‡) 
Paracetamol use 
vs control [OR 
(95% CI)] 
- - - - - Nursing home vs 
community 2.52 
(1.35 to 4.73)§ 
NSAID use % 
(control %) 
58 (paracetamol 
and NSAID) 
- - - - 5.9 (12†, 3.8‡) 
NSAID use vs 
control [OR (95% 
CI)] 
 - - - - 0.32 (0.07 to 1.42)§ 
Opioid use % 
(control %) 
13 - - - 27.5 (16.9) 
Weak 14.9 (12.4) 
Strong 17.4 (7.1) 
14.3 (8†, 30.1‡) 
Opioid use vs 
control [OR (95% 
CI)] 
- - - - All 1.27 (1.22 to 
1.31); 
buprenorphine 2.57 
(2.41 to 2.74); 
fentanyl 2.28 (2.12 
to 2.46) 
Nursing home vs 
community 2.84 
(1.33 to 6.07)§ 
Non-pharm (%) - - - - - - 
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Table 2 cont. Summary of pharmacological pain treatment studies 
Author Brummel-Smith et 
al38 
Gallini et al54 Gilmartin et al47 Hamina et al48 Hamina et al55 Barry et al40 
Design Cross-sectional Cohort, nested 
case control 
Cohort Cohort Cohort Cross-sectional 
Origin USA France Finland Finland Finland Northern 
Ireland 
Diagnosis Dementia AD AD AD AD Dementia 
n (reference)† 154 (255) 595 236¶ 62,074 (62,074) 67,215 (67,215) 75¶ 
Quality Poor Fair Good Good Fair Fair 
Analgesic use % 
(control %) 
49 received >1 26 
13 persistent 
13.6, 10.6, 13.7, 
16.8, 15.3§§ 
- 34.9 (33.5) 40 
20 taking ≥2 
Analgesic use, 
PWD vs control 
[OR (95% CI)] 
- - - - 2011 vs 2005 [2.34 (2.24 to 
2.45)] 
- 
Paracetamol use 
% (control %) 
14 67.5¶¶ 5.5, 5.6, 5.4, 
13.0, 11.1§§ 
- 25 (19.1) 32 
Paracetamol use 
vs control [OR 
(95% CI)] 
- - - - - - 
NSAID use % 
(control %) 
21 31.2¶¶ 8.1, 4.0, 7.7, 3.1, 
4.1§§ 
- 13.2 (17.3) 8 
NSAID use vs 
control [OR 
(95% CI)] 
- - - - 2011 vs 2005 [0.73 (0.69 to 
0.77)] 
- 
Opioid use % 
(control %) 
13 36.2¶¶ 1.3, 1.5, 3.0, 2.3, 
1.4§§ 
All 21.1 (26.8); 
Long term 7.2 (8.7) 
All 7.1 (8.3); Weak 5.0 
(6.9); Buprenorphine 1.4 
(0.9); Strong 
1.3 (1.1); Fentanyl 0.8 (0.6)  
16 
Opioid use vs 
control [OR 
(95% CI)] 
- - - - 2011 vs 2005 [3.78 (3.44 to 
4.15)] 
- 
Non-pharm (%) - - - - - - 
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Table 2 cont. Summary of pharmacological pain treatment studies 
Author Bell et al56 Hunt et al44 Thakur et al57 Breland et al58 Li et al37 Shega et al59 
Design Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional Cross-sectional 
Origin Finland USA USA USA USA USA  
Diagnosis 
(subtype) 
AD Dementia Dementia Dementia Dementia Dementia 
n (reference)† 28,089 (28,089) 802 (802) 202 136 203 115¶ 
Quality Fair Poor Fair Fair Fair Fair 
Proportion taking 
analgesic % 
(control %) 
- 69.7†† 56†† 49 59.7 32†† 
15‡‡ 
 
Analgesic - pwd 
vs control [OR 
(95% CI)] 
- - - - - - 
Paracetamol % 
(control %) 
- - - 40 (non-
narcotics) 
32.5 (paracetamol/NSAID) 19†† 
8‡‡ 
Paracetamol use 
vs control [OR 
(95% CI)] 
- - - - - - 
NSAID % (control 
%) 
- - - 40 (non-
narcotics) 
32.5 (paracetamol/NSAID) 8†† 
8‡‡ 
NSAID use vs 
control [OR (95% 
CI)] 
- - - -  - 
Opioid % (control 
%) 
All 3.56 (4.62); 
Weak 2.68 (3.83); 
Strong 0.95 (0.76) 
- - 9 Weak 16.8   
Strong 1.5 
4†† 
0‡‡ 
Opioid vs control 
[OR (95% CI)] 
All 0.77 (0.71 to 0.84); 
Weak 0.70 (0.64 to 
0.77); Strong 1.26 
(1.05 to 1.51); 
Fentanyl 1.44 (1.13 to 
1.83). 
- - - - - 
Non-pharm (%) - - - - Exercise 45.8 - 
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Table 2 cont. Summary of pharmacological pain treatment studies 
Author Regier & Gitlin60 Nakanishi et al62 Hamina et al49 Grace et al61 
Design Cross-sectional Before-after (baseline data) Cohort Cross-sectional 
Origin USA Japan Finland USA 
Diagnosis (subtype) Dementia Dementia AD Dementia 
n (reference) 596¶ 219 24,747 total n 
3327 opioid initiators (3325 non-
opioid initiators) 
543 
Quality Fair Poor Good Fair 
Proportion taking analgesic % 
(control %) 
40.1 24.7 - 22 Caucasian 
30 African American 
17 Latino 
Analgesic - pwd vs control [OR 
(95% CI)] 
- - - - 
Paracetamol % (control %) - - 58.9 (21.5) (non-opioid initiators) - 
Paracetamol use vs control [OR 
(95% CI)] 
- - - - 
NSAID % (control %) - - 16.4 (3.6) (non-opioid initiators) - 
NSAID use vs control [OR (95% 
CI)] 
- - - - 
Opioid % (control %) - - 13.44 (total n) - 
Opioid vs control [OR (95% CI)] - - - - 
Non-pharm (%) - - - - 
Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; NSAID, Non-Steroid Inflammatory Inhibitors; OR, Odds Ratio; PWD, people with dementia, USA, United 
States of America  
The control/reference group is community-dwelling people without dementia unless noted otherwise. However, for Haasum (2011) community-dwelling people without 
dementia (†) is labelled regardless for clarification between the multiple reference groups. 
† people without dementia living in the community 
‡ people with dementia living in a nursing home 
§ comparison of nursing home dwelling people with dementia to community-dwelling people with dementia as the reference population. 
¶ dyadic paired participants (e.g. person with dementia and their caregiver). 
†† analgesic medication in a sample of people with dementia reporting pain 
‡‡ analgesic medication in a sample of people with dementia reporting no pain  
§§ baseline, year 1, year 2, year 3, year 4, and year 5. 
¶¶ percentage of each analgesic in a sample of people with dementia prescribed analgesic medication 
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Table 3 Studies evaluating the utility and effectiveness of treatments for pain.   
Author Elliott & Horgas64 Benedetti et al63 Park65 Nakanishi et al62 Kunik et al45 
Design Before-after ABAB 
within subjects 
Non-RCT Before-after ABAB within 
subjects 
Before-after RCT 
Sub-theme Pharmacological Pharmacological Non-pharmacological Non-pharmacological Non-pharmacological 
Origin USA Italy USA Japan USA 
Quality Poor Fair Poor Poor Poor 
Diagnosis 
(subtype) 
Dementia AD Dementia Dementia Dementia 
n (reference/ 
control) 
3 38 (16) 15 219 101¶ (102¶) 
Pain 
assessment 
Coded pain 
behaviours 
NRS M-PADE Abbey Pain Scale PGC PIS 
Intervention Paracetamol 1.3g 
every 8hrs during 
treatment phases 
Open-hidden application 
of 1% lidocaine during 
insertion of needle 
Preferred music initiated 30 
minutes prior to peak agitation 
time. 
2-day training course, a 
web-based tool for 
ongoing monitoring and 
assessment for 
challenging behaviour, 
and multi-agency 
discussion meetings for 
formal caregivers. 
6 to 8 weekly sessions 
of 45-minute home 
visits targeted to 
informal caregivers. 
Improving: caregivers 
pain recognition, 
communication, making 
daily activities pleasant 
Follow up 24 day follow up.  1 year 8 week A = Baseline = 3, 4, 7, 
8. B = Week 1, 2, 5, 6. 
6 months 3, 6, 12 months 
Results  
(A = baseline,  
B = 
Intervention) 
Ppt 1: 32.1 (A1), 18.6 
(B1), 27.5 (A2), 17.5 
(B2) Ppt 2: 33 (A1), 
22.5 (B2), 31.1 (A2), 
20.1 (B2) Ppt 3: 57.8 
(A1), 30 (B1), 53.3 
(A2), 29.8 (B2). 
The effects of the open 
treatment lowered in AD 
after 1 year (t(27) = -
5.151, p<.001). 
Pain during vs before (p=.06) 
Pain during vs after (p=.86). 
Intervention weeks vs baseline 
(p=.22). Pain after vs before 
(t=2.21; df=28; p<.05) 
Decreased pain after 
the intervention 
compared to before 
(t(218)=2.63, p=.009). 
No difference in 
analgesics after the 
intervention compared 
to before (X2(1)=2.00, 
p=0.5). 
Decreased pain over 
time for treatment group 
(PWD overall pain: F(3, 
412) = 4.59, p=.004. No 
difference between 
groups. 64% of 
caregivers highlighted 
skills: recognising signs 
of pain, pain treatment 
with analgesic or other 
strategies. 
¶ dyadic paired participants (e.g. person with dementia and their caregiver). 
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USA United States of America, NRS numerical rating scale, AD Alzheimer’s Disease, PGC Philadelphia Geriatric Centre, PIS Pain Intensity Scale, PWD 
person with dementia, M-PADE Pain Assessment in Dementing Elderly, RCT randomised control trial 
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Figure 1 PRISMA flow chart 
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Figure 2 Percentage of pain self-reported by people with dementia compared to informant-reported 
pain by an informal caregiver  
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Figure 3 Percentage of opioid analgesics for people with dementia and comparator groups without 
dementia. 
